The size of the global wearable injectors market was worth USD 9.40 billion in 2024. The global market is anticipated to grow at a CAGR of 10.5% from 2025 to 2033 and be worth USD 23.09 billion by 2033 from USD 10.39 billion in 2025.
The rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease drives the wearable injectors market. Chronic conditions necessitate regular injections that can be given daily or weekly, so patients need injections that can be given every 2-6 months. However, this kind of injection involves many medications, which can only be met by wearable injections that administer 2 – 10 ml of medication. According to the National Health Interview Survey (NHIS), about 51.8 % of U.S. adults have one chronic disease, while 27.2% have several chronic diseases. According to the WHO, chronic diseases are responsible for almost 38 million deaths yearly.
Furthermore, according to the IDF Diabetes Atlas Ninth Edition 2019, about 463 million adults (20-79 years) have diabetes. This number is expected to grow to 700 million by 2045, with 79% of adults with diabetes residing in low and middle-income countries. Furthermore, according to the World Health Organization, cancer is the leading cause of death worldwide, accounting for almost 10 million deaths in 2020, while the American Cancer Society journal predicts that in 2021, there were 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States. Furthermore, according to WHO, cardiovascular diseases (CVDs) are the leading cause of death worldwide, affecting an estimated 17.9 million lives per year; as these cases increase, the need for advanced technological injections like wearable injections increases.
Biologics are usually delivered intravenously, subcutaneously, or intramuscularly and are inappropriate for oral administration. As a result, as the market for biologics grows, so does the demand for wearable injectors. Besides, many individuals worldwide suffer from rare diseases that new biologic methods can help with. Wearable injectors are one solution that allows these patients to self-administer the biologics rather than attending hospitals. In addition, patient-centric biologics and their transition from intravenous (IV) infusion to subcutaneous injection drive demand for wearable injectors.
The use of alternative drug delivery options impedes the demand for wearable injectors. Since injectables are painful, patients choose other routes, such as oral, topical, and nasal. Most patients favored the oral medication path since it is more cost-effective, reliable, and simple. In contrast, patients are not entirely trained and secure about injectables, so they choose other routes. Furthermore, wearable injectors necessitate specialist supervision and hospital appointments, resulting in a steady reduction in demand for wearable injectors.
REPORT METRIC |
DETAILS |
Market Size Available |
2024 to 2033 |
Base Year |
2024 |
Forecast Period |
2025 to 2033 |
Segments Covered |
By Type, Technology, Application, End-User, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis; Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Based on the type, the on-body segment is expected to hold a major global market share during the forecast period. On-body injectors provide comfort and ease of use, water resistance and flexible dosing options, and the ability to reheat refrigerated medications automatically. On-body injectors have become more popular because of these advantages. The On-body Injector is often inserted on the stomach or behind the arm. A nurse typically gives it on the last day of each chemotherapy cycle. As a result, one of the key market drivers is the growth in the incidence of cancer and CVDs.
On the other hand, since these devices are free of skin fitting issues and allergic skin reactions, the market for off-body injectors is expected to grow at the fastest CAGR throughout the forecast period.
Based on the technology, in 2024, the spring-based segment dominated the market, and it is expected to continue to do that throughout the forecast period owing to the growing popularity of adhesive patches, which are user-friendly devices that allow patients to accurately deliver drugs by pressing one or more buttons on the device. Furthermore, due to rising customer demand for these devices, which are more comfortable to use than others, the motor-driven segment is predicted to grow faster over the forecast period.
Based on the application, the oncology segment had the leading share of the worldwide wearable injectors market in 2024. On the other hand, owing to the increased incidence of diabetes and the increasing acceptance of wearable injectors due to their competitive advantage over insulin pumps, the Autoimmune diseases segment is predicted to be the fastest-growing segment throughout the forecast period.
Based on region, the North American wearable injectors market accounted for the largest global market share in 2021 and is estimated to continue playing the leading role throughout the forecast period. The regional market for wearable injectors is anticipated to be driven by factors such as the increased incidence of chronic diseases, favorable reimbursement scenarios, and significant industry participants in the region. According to the American Diabetes Association, diabetes has a more significant health impact on Americans than heart disease, substance use disorder, or COPD, with 30.5 million people diagnosed and millions more at risk. The rising frequency of these diseases is projected to fuel demand for wearable injectors throughout the region.
The Asia Pacific wearable injectors market is predicted to be the fastest-growing regional market throughout the forecast period. This can be attributed to the region's growing elderly population, particularly in Japan, a large diabetic population in China, and chronic diseases.
During the forecast period, the European wearable injectors market is estimated to rise at a promising CAGR.
The Latin American wearable injectors market is anticipated to hold a considerable share of the global market in the coming years.
The wearable injectors market in MEA is estimated to register a moderate share worldwide during the forecast period.
Some of the promising companies operating in the global wearable injectors market profiled in this report are Amgen, Becton, Dickinson and Company, Medtronic, Valeritas, Inc, Insulet Corporation, Gerresheimer AG (Sensile Medical), Tandem Diabetes Care, SteadyMed Therapeutics, Inc., United Therapeutic Corporation, Sensile Medical AG, Zealand Pharma A/S (Valeritas, Inc.), West Pharmaceutical Services, Inc., SteadyMed Therapeutics, F. Hoffmann-La Roche Ltd, Ypsomed, Johnson & Johnson, Dexcom, Inc., Enable Injections, CeQur SA, Sensile Medicals, Bespak, and many others.
These players focus on strategies like product launches, partnerships, acquisitions, and geographic expansion to gain a competitive advantage. These include, On 4 February 2021, Phillips-Medisize and MedTech devices are collaborating with Subcuject, a leading innovator of proprietary device platforms, to deliver a groundbreaking wearable bolus injector that is low-cost, patient-friendly, and prefilled for single-use. Additionally, on 14 July 2020, Sorrel Medical, a company specializing in developing wearable drug delivery systems, opened a new manufacturing facility in Israel that will produce wearable injectors. Sorrel's wearable injectors allow clinical trials for large-volume and high-viscosity drugs in homecare settings.
This research report on the global wearable injectors market has been segmented and sub-segmented into the following categories.
By Type
By Technology
By Application
By End-use
By Region
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region